Copyright
©2010 Baishideng.
World J Gastroenterol. Feb 14, 2010; 16(6): 683-690
Published online Feb 14, 2010. doi: 10.3748/wjg.v16.i6.683
Published online Feb 14, 2010. doi: 10.3748/wjg.v16.i6.683
Authors | Antifibrotic agent studied | Patient group (n) | Dose used | Therapeutic efficacy |
Kershenobich et al[33], 1988 | Colchicine | Cirrhosis - all causes (100) | 0.6-1.8 mg/d | 5-yr survival rates: colchicine 75%, placebo 34%; Histological improvement: colchicine 30%, placebo 0% |
Pockros et al[34], 2007 | IFN-γ | Cirrhosis - HCV-related (488) | IFN-γ 1b 100 mg and 200 mg | Histological improvement in select group with IFN-inducible T cell a chemoattractant (I-TAC), |
Weng et al[35], 2005 | IFN-γ | Cirrhosis - HBV-related (99) | 50 mg IFN-γ intramuscularly on a daily basis for 3 mo | Histological improvement: treatment group 63%, control group 24.1% |
Debernardi-Venon et al[36], 2007 | Angiotensin II receptor blockers (candesartan) | Cirrhosis - all causes (47) | 8 mg/d | Has been shown to decrease hepatic venous pressure gradient in patients with cirrhotic portal hypertension; studies investigating histological improvement still underway |
Neuschwander-Tetri et al[37], 2003 | PPAR ligands (rosiglitazone) | NASH associated fibrosis (30) | 4-8 mg/d | Significant improvements in zone 3 perisinusoidal fibrosis |
Armendáriz-Borunda et al[38], 2006 | Pirfenidone | HCV-related fibrosis (15) | 1200 mg/d | Histological improvement in 30% of patients |
Ferenci et al[39], 1989 | Silymarin | Cirrhosis - all causes (170) | 140 mg three times daily | 4-yr survival rate: silymarin 58%, placebo 39%; no histopathological studies available |
Nelson et al[40], 2003 | Interleukin-10 | HCV related fibrosis (30) | subcutaneously at a daily or thrice weekly dose of 8 pg/kg or a thrice weekly dose of 4 pg/kg | Significant improvements in histology |
Poupon et al[41], 2003 | Ursodeoxycholic acid | PBC (367) | 15-20 mg/kg per day | Significantly delayed progression of histopathological changes |
Lieber et al[42,43], 2003 | Polyenylphosphatidylcholine | Chronic alcoholics (789) | 1.5 g three times daily | No improvement in fibrosis; new study underway |
- Citation: Shorbagi A, Bayraktar Y. Experience of a single center with congenital hepatic fibrosis: A review of the literature. World J Gastroenterol 2010; 16(6): 683-690
- URL: https://www.wjgnet.com/1007-9327/full/v16/i6/683.htm
- DOI: https://dx.doi.org/10.3748/wjg.v16.i6.683